Genzyme at buy by Jefferies

Jefferies & Co., Inc. analyst Adam Walsh rated Genzyme Corp. at a buy after the company announced positive two-year interim results from the three-year, 334-patient phase 2 trial comparing Campath with Rebif for the treatment of multiple sclerosis. The analyst believes the total market for Campath could exceed $500 million as several ongoing trials are under way to expand its use. Shares of the Cambridge, Mass.-based biotechnology company were up 46 cents, or 0.67%, at $68.81. (Nasdaq: GENZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.